about
Behavioral health screening and intervention for women in Argentina: a preliminary model for the childbearing yearsBuprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and childNeonatal abstinence syndrome after methadone or buprenorphine exposureBuprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry.Commentary on Mactier et al. (2014): Methadone-assisted treatment and the complexity of influences on fetal development.Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National GuidanceTwice stigmatized: provider's perspectives on drug-using women in the Republic of GeorgiaNeonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration.Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women.The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse.Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center.Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.Process and product in cross-cultural treatment research: development of a culturally sensitive women-centered substance use intervention in georgiaFetal neurobehavioral effects of exposure to methadone or buprenorphine.The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.Fetal assessment before and after dosing with buprenorphine or methadoneScreening for Mood Disorder in Pregnant Substance-dependent PatientsPregnant and nonpregnant women in cape town, South Africa: drug use, sexual behavior, and the need for comprehensive servicesInitial feasibility of a woman-focused intervention for pregnant african-american women.Reinforcement-based treatment improves the maternal treatment and neonatal outcomes of pregnant patients enrolled in comprehensive care treatment.Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.Neonatal neurobehavior effects following buprenorphine versus methadone exposure.Use of buprenorphine in pregnancy: patient management and effects on the neonate.Suicidal Ideation Among Drug-Dependent Treatment-Seeking Inner-City Pregnant Women.Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphineDouble jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trialMaternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learnedBuprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.Cigarette Smoking and Neonatal Outcomes in Depressed and Non-Depressed Opioid-Dependent Agonist-Maintained Pregnant Patients.Behavioral treatment + naltrexone reduces drug use and legal problems in the Republic of Georgia.Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxificationHIV Sexual and Drug-Use Risk in Drug-Dependent Pregnant Patients in Comprehensive Drug Treatment.The efficacy of escalating and fixed contingency management reinforcement on illicit drug use in opioid-dependent pregnant womenA Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal OutcomesCorrelates of lifetime trauma exposure among pregnant women from Cape Town, South Africa.
P50
Q26800245-BB2A4306-5E7F-4695-9036-23B15C3B6A7FQ28073116-FEA91DE0-29C2-4237-9478-814D79BBC8BFQ30499416-552D2542-739D-4754-868B-F20F05DE19F5Q30619876-78E03085-952F-4ECE-882A-BC64643ACFDEQ33432721-29ACE792-91BC-44E0-A0C0-A15741C57BB2Q33678149-05B4C728-114B-40B2-96BD-B511B00982DDQ33760424-A46D88FE-6137-4598-A5CF-FD4C5078C874Q33971403-95D0BB87-F627-4A34-BB8A-E20BA29C879EQ33982854-5A5AE1D5-3183-4D30-9F64-0C9B3721D28DQ34025985-892BE199-A4F7-43F2-9A32-09453D28AE61Q34076552-35B9D8A9-911F-4825-85E5-8E2D9E874E92Q34078429-B9B49437-33F0-479D-BD57-839DF9C741DBQ34117716-D859873F-0643-49DD-B74F-6B1FE9179CDAQ34186492-365C42C8-4934-463A-863C-AE2BA57AD6FFQ34308203-B30BD6B6-7843-49E0-B630-3A4967026B51Q34581552-9BF8AAE0-40A2-47E3-A387-879C7D49CD4BQ34676425-00B804CB-A732-4168-8351-FFED636CFE12Q34721038-838F9EB6-8982-483D-B64A-BC47C3FEF723Q34721065-46E29469-6461-4573-BF04-BD7D7B627178Q34775584-35D3627C-984C-4456-AEDB-23DD31302EE0Q34856114-A44D7BF8-E8A8-4868-8B43-5E5E958FD6DAQ34877072-AE6866F5-B896-4008-BDFB-375322153FE2Q34877114-8E1ABCCF-1DC8-4572-9D16-28654EF2DF33Q34886724-64624145-17E1-4E84-AB26-C623803B9B77Q35044036-F8FDD600-13F3-46D5-A893-720D3273F1F1Q35112402-BF069307-C584-4357-A3D3-A01245971940Q35124209-CBB2ECB6-57D8-4B97-A457-EB6E202D4CFEQ35126008-675FA480-0042-4B25-A30C-0E4D26E72946Q35201603-105F0CCD-8CE7-4130-A062-3E022100F01EQ35818263-0B92E0AD-8EC4-4B7E-905F-40F63BBA141CQ35835534-E1BFD284-4B12-46D2-A544-DA1C8424C984Q35863900-B75E9AF6-99F2-48F8-8EAB-4FBE6914F060Q36036257-7C338A13-6DD9-4516-87AA-B5A22060D743Q36107343-937F3C98-5C80-47F7-880F-17391EC0B45EQ36145806-9260716A-8951-419B-A43C-3BDB8FF5BE19Q36172571-DCC6BBF8-E712-4E37-9935-9ECB585E09C1Q36288433-E0072CF5-6B57-4F74-8DEE-1F867416FEE5Q36441686-1B5DDB22-AAC1-4568-9D5E-CB2E7421D7D2Q36702592-21F3B5FC-E932-488C-91AE-80012C52DBC3Q36788038-BEFCE0F8-9FE5-497E-B1B7-A00EC1EAB2EF
P50
name
Hendrée E Jones
@ast
Hendrée E Jones
@en
Hendrée E Jones
@nl
type
label
Hendrée E Jones
@ast
Hendrée E Jones
@en
Hendrée E Jones
@nl
prefLabel
Hendrée E Jones
@ast
Hendrée E Jones
@en
Hendrée E Jones
@nl